Abstract
Tacrolimus (Tac) is an immunosuppressive drug with a narrow therapeutic width and highly variable pharmacokinetics. Therefore, monitoring of Tac blood concentrations is of utmost importance in the management of renal transplant recipients. The occurrence and intensity of adverse effects depend on blood concentration and total exposure of the organism to this drug. This implies finding a new gender-dependent predictable method for Tac exposure monitoring based on determination of the area under the time concentration curve (AUC). The primary aim of this study was to investigate gender differences in systemic body exposure to Tac in renal transplant patients after the first oral dose and in a steady state by determining 12-h AUC (AUC0–12). The secondary objective was to find the best sampling time in which measured Tac concentration best predicts AUC value with respect to gender. Tac pharmacokinetic study was conducted in 20 kidney transplant recipients (10 men/10 women) on quaternary immunosuppressive therapy. The first oral Tac dose (0.05 mg/kg) was given on the fifth day post-transplant. After reaching steady state, regimen stabilized and dosage was adjusted in accordance with the level of Tac. Blood concentrations were measured by microparticle enzyme immunoassay method. AUC0–12 for each patient was calculated after the first oral Tac dose and in the steady state from a plot of Tac concentration versus time from 0 to 12 h using the trapezoid rule. Associations between each sampling time point of concentrations within 12 h after the administration and AUC0–12 were evaluated by Pearson correlation coefficients. Abbreviated sampling equations were derived by multiple stepwise regression analyses. Statistically significant difference was found in AUC0–12 between male and female patients after the first oral dose (p < 0.01), but this difference was lost in a steady state. In female recipients C2 seemed to be good indicator of total body exposure to Tac after the first oral dose and this was also confirmed in a steady state. The three-point sampling method was required for calculating AUC after the first oral dose in male patients, whereas in the steady state, concentration of C8 seemed to be a good indicator of abbreviated AUC for a Tac monitoring strategy in male patients. Non-compartment Tac pharmacokinetic and regression analysis showed gender difference in total Tac exposure and determined the best predictable Tac concentrations after the first oral dose. Our study confirmed gender-dependent pharmacokinetics in a steady state in terms of best sampling time in which measured Tac concentration best predicts AUC value.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anil Kumar M, Irfan Saeed M, Ranganna K et al (2008) Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes. Transpl Immunol 20:32–42
Balbontin FG, Kiberd B, Squires J et al (2003) Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. Transpl Proc 35:2445–2448
Chen Y, Zhang KL, Chen L et al (2005) Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolat mofetil and prednisone in chinese renal transplant recipients. Transpl Proc 37:4246–4250
Flechner SM, Kobashigawa J, Klintmalm G (2008) Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 22:1–15
Greanya ED, Poulin E, Partori N et al (2012) Pharmacokinetics of Tacrolimus and micophenolat mophetil in renal transplant pacients on a corticosteroid-free regiment. Am J Health Syst Pharm 69:134–142
Greenblatt Đ, Moltke LL (2008) Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48:1350–1355
Hon Y, Chamberlain C, Kleiner D et al (2010) Evaluation of Tacrolimus abbreviated area-underthe-curve monitoring in renal transplant patients who are potientially at risk for adverse events. Clin Transplant 24:557–563
Hoshinaga K, Aikawa A, Murai M et al (2005) A Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. Transpl Proc 37:1762–1763
Kuypers DR (2005) Immunosuppressive drug monitoring—what to use in clinical practice today to improve renal graft autcome. Transpl Int 18:140–150
Kuypers D, Naesens M, Jonge H et al (2010) Tacrolimus dose requirement and CYP 3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Drug Monit 4:394–404
Lemahieu WP, Maes BD, Verbeke K et al (2004) Alternation of CYP3A4 and P-glikoprotein activity in vivo with time in renal graft recipients. Kidney Int 66:433–440
Lemahieu WP, Maes BD, Vanrenterghem Y (2005) Different evolution of trough and dose levels during the first year after transplantation for tacrolimus versus cyclosporine. Transplant Proc 37:2051–2053
Martins L, Ventura A, Branco MJ et al (2004) Cyclosporine versus tacrolimus in kidney transplantation: are there differences in nephrotoxicity? Transpl Proc 36:877–879
Mathew SS, Flemind DH, Jeyaseelan V (2008a) A limited sampling strategy for Tacrolimus in renal transplant patients. Br J Clin Pharmacol 66:467–472
Mathew BS, Fleming DH, Jeyaseelan V et al (2008b) A limited sampling strategy for tacrolimus in renal transplant patients. Br J Clin Pharmacol 66:467–472
Ohtani H, Barter Z, Aarabi M et al (2012) A retrospective comparation of the efficacy and safety in kidney transplant recipients with basiliximab and antithymocite globulin. Chin Med J 125:1235–1240
Paine MF, Ludington SS, Chen ML et al (2005) Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression? Drug Metab Dispos 33:426–433
Press RR, Ploeger BA, Den Hartigh J et al (2009) Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 31:187–197
Satoh S, Kagaya H, Saitro M et al (2008) Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol 66:208–214
Schiff J, Cole E, Cantarovich M (2007) Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2:374–384
Scholten EM, Cremers CLM, Schoemaker RC et al (2005) AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 67:2440–2447
Schwartz JB (2007) The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 82:87–96
Sprangers B, Kuypers DR, Vanrenterghem Y (2011) Immunosuppression: does one regimen fit al? Transplantation 92:251–261
Velickovic-Radovanovic R, Mikov M, Catic-Djordjevic A et al (2012) Tacrolimus as part of immunosuppressive treatment in kidney transplantation patients-sex differences. Gend Med 9:471–480
Velickovic-Radovanović R, Mikov M, Paunović G et al (2011) Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients. Gend Med 8:23–31
Veličković-Radovanovic R, Paunovic G, Mikov M et al (2010) Clinical pharmacokinetics of tacrolimus after the first oral administration in renal transplant recipients on triple immunosuppressive therapy. Basic Clin Pharmacol Toxicol 106:505–510
Weber LT (2007) Verbesserung der Arzneimittelsicherheit durch Therapiemonitoring. Monatsschrift Kinderheilkunde 8:724–732
Wolbold R, Klein K, Burk O et al (2003) Sex a major determinant of CYP3A4 expression in human liver. Hepatology 38:978–988
Wong KM, Shek C, Chan KF et al (2000) Abbreviated tacrolimus area-under the curve monitoring for renal transplant recipients. Am J Kidney Dis 35:660–666
Acknowledgments
This study was supported by grant of Ministry of Science and Technological Development of Serbia—Project Number 41018 and 41012.
Conflict of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Velickovic-Radovanovic, R., Mikov, M., Catic-Djordjevic, A. et al. Gender-dependent predictable pharmacokinetic method for tacrolimus exposure monitoring in kidney transplant patients. Eur J Drug Metab Pharmacokinet 40, 95–102 (2015). https://doi.org/10.1007/s13318-014-0184-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13318-014-0184-y